ArticleClinical and molecular hepatology2023
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.
Article in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Prevalence and clinical impact of hepatic steatosis on autoimmune liver disease: A systematic review and meta-analysis.Hepatology communications · 2026Pooled it
- Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306).Clinical and molecular hepatology · 2025Pooled it
- Meta-analysis: accuracy of the Baveno VI criteria for the diagnosis of high-risk varices in patients with hepatocellular carcinoma.Frontiers in oncology · 2024Pooled it
- Characterisation of liver disease using quantitative MRI: report of the imaging arm of the ELEGANCE study.BMC gastroenterology · 2026Article
- Recent Advances in the Diagnosis and Management of Clinically Significant Portal Hypertension in Liver Cirrhosis: A Clinical Review.Biomedicines · 2026Review
- Noninvasive Tests for Predicting Decompensation in Compensated Advanced Chronic Liver Disease: A Comprehensive Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Review
- Prognostication of Liver Disease Patients via the WFUMB 'Rule-of-4' Algorithm Using SSI-2D-SWE-Based Liver Stiffness Measurement.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Prognostic Impact of Varices and Hemorrhagic Events in Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab.Gut and liver · 2026Article
- Blood-based Vienna 3P/5P risk models accurately predict first hepatic decompensation in compensated advanced chronic liver disease.JHEP reports : innovation in hepatology · 2026Article
- Acute Changes in Liver and Spleen Stiffness Following Endoscopic Variceal Ligation in Advanced Liver Disease-A Pilot Study.Journal of clinical medicine · 2026Article
- Correspondence to editorial 1 on "Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis".Clinical and molecular hepatology · 2026Article
- Editorial on "Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study".Clinical and molecular hepatology · 2026Article
- The evolution of non-invasive strategies in cirrhosis management-from screening to precision monitoring: Editorial on "Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an international multicenter study".Clinical and molecular hepatology · 2026Article
- Should direct-acting antiviral be considered for all patients with HCV-related hepatocellular carcinoma?: Reply to correspondence on "Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study".Clinical and molecular hepatology · 2026Article
- EASL postgraduate course report: Vascular biology in chronic liver disease and clinical management implications.JHEP reports : innovation in hepatology · 2025Review
- How to improve the care of decompensated cirrhosis: the intervention model for chronic disease management.Hepatobiliary surgery and nutrition · 2025Article
- Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis.Clinical and molecular hepatology · 2025Article
- Advances in the diagnosis and management of clinically significant portal hypertension in cirrhosis: A narrative review.World journal of hepatology · 2025Review
- Preventing the progression of cirrhosis to decompensation and death.Nature reviews. Gastroenterology & hepatology · 2025Review
- Acute and non-acute decompensation of liver cirrhosis.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
12 authors at 6 institutions in 4 countries.
Funding
Abstract
BACKGROUND/
aimsThe utility of Baveno-VII criteria of clinically significant portal hypertension (CSPH) to predict decompensation in compensated advanced chronic liver disease (cACLD) patient needs validation. We aim to validate the performance of CSPH criteria to predict the risk of decompensation in an international real-world cohort of cACLD patients.
methodscACLD patients were stratified into three categories (CSPH excluded, grey zone, and CSPH). The risks of decompensation across different CSPH categories were estimated using competing risk regression for clustered data, with death and hepatocellular carcinoma as competing events. The performance of "treating definite CSPH" strategy to prevent decompensation using non-selective beta-blocker (NSBB) was compared against other strategies in decision curve analysis.
resultsOne thousand one hundred fifty-nine cACLD patients (36.8% had CSPH) were included; 7.2% experienced decompensation over a median follow-up of 40 months. Non-invasive assessment of CSPH predicts a 5-fold higher risk of liver decompensation in cACLD patients (subdistribution hazard ratio, 5.5; 95% confidence interval, 4.0-7.4). "Probable CSPH" is suboptimal to predict decompensation risk in cACLD patients. CSPH exclusion criteria reliably exclude cACLD patients at risk of decompensation, regardless of etiology. Among the grey zone, the decompensation risk was negligible among viral-related cACLD, but was substantially higher among the non-viral cACLD group. Decision curve analysis showed that "treating definite CSPH" strategy is superior to "treating all varices" or "treating probable CSPH" strategy to prevent decompensation using NSBB.
conclusionNon-invasive assessment of CSPH may stratify decompensation risk and the need for NSBB in cACLD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.